Abeona Therapeutics’ (ABEO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note released on Tuesday, Benzinga reports. The firm currently has a $36.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Abeona Therapeutics from a hold rating to a sell rating in a research note on Tuesday.

Abeona Therapeutics Trading Up 0.6 %

ABEO opened at $3.19 on Tuesday. Abeona Therapeutics has a 1-year low of $2.83 and a 1-year high of $9.01. The stock’s fifty day simple moving average is $7.37 and its 200 day simple moving average is $5.63. The stock has a market cap of $87.25 million, a PE ratio of -1.22 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). Equities analysts forecast that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplex Trading LLC grew its holdings in Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 13,418 shares in the last quarter. Jump Financial LLC acquired a new position in Abeona Therapeutics in the 4th quarter valued at $199,000. Schonfeld Strategic Advisors LLC acquired a new position in Abeona Therapeutics in the 3rd quarter valued at $648,000. Worth Venture Partners LLC grew its holdings in shares of Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 121,969 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after purchasing an additional 185,638 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.